



Corporate Presentation

April 2020



This presentation contains confidential information and is intended for information purposes only. This presentation is proprietary to Botanapharm and intended solely for the use of the individual or entity to whom it is addressed and is not to be disseminated, distributed or copied.

About Botanapharm

Botanapharm Pty Limited (ACN 629 565 902) is a private Australian company looking to become a global leader in the emerging global cannabis market.

- Interests in Lesotho, Zimbabwe, South Africa and Malta.
- Several JVAs signed.
- Planned National Stock Exchange of Australia/Deutsche Bourse joint listing in 2020 at market capitalisation of A\$14 million.



Botanapharm

Botanapharm is looking to simultaneously list on the National Stock Exchange of Australia (NSX) and Deutsche Bourse.

Botanapharm will raise seed capital of A\$500,000 before a A\$2 million prospectus raising. Funds will be used to establish and expand Botanapharm's cannabis operations.

Share type	Shares (m)	Capital (A\$m)	%
Shares on issue	110.00	–	78.6
Seed raising (A\$0.05)	10.00	0.50	7.1
Prospectus raising NSX (A\$0.10)	20.00	2.00	14.3
Costs of listing	–	–0.30	–
Total	140.00	2.20	100.0

The Cannabis Genus



Cannabis is a genus of plant comprising several species.

Cannabis is an annual crop that grows in the warmer months, usually starting from mid Spring, with harvest in late Autumn.

Cannabis has a long history of human use, especially but not limited to the treatment of numerous medical conditions.

Scientific evidence of Cannabis' effectiveness in treating a number of serious medical conditions is now becoming widely available.

There are three recognised species of Cannabis:

- *Cannabis sativa*
- *Cannabis indica*, and
- *Cannabis ruderalis*.

With years of hybridisation, most modern varieties have combined genetics of two or more species.



The medicinal phytochemicals in cannabis are known as cannabinoids. Over 100 cannabinoids have so far been identified. Cannabinoids are concentrated in the female flower of the plant, which is the material harvested for medical use.

The two main cannabinoids studied for medicinal use are tetrahydrocannabinol (THC) and cannabidiol (CBD), which have been indicated for treating conditions such as:

- certain types of epilepsy
- glaucoma
- autoimmune diseases
- side effects of chemotherapy in cancer patients, and
- pain management—especially in complex pain.



After years of selective breeding, commercial cannabis strains are usually hybrids of *Cannabis sativa* and *Cannabis indica*.

Botanapharm will grow commercialised hybrids of these species to ensure consistent quality.

Hybrids of these species are photo-sensitive, meaning they will change from vegetative growth to flower production in response to a shortening day length at the end of summer, resulting in a harvest time of mid- to late Autumn.

Botanapharm will produce different varieties with varying concentrations and ratios of THC and CBD to tailor products to certain medical conditions.




Hybrids of *Cannabis ruderalis* are auto-flowering, meaning they are not photosensitive and will begin flowering to produce harvestable material within about 70 days.

A percentage of **Botanapharm's** production will include auto-flowering varieties, allowing for first harvest within 70 days of production commencing.

Botanapharm will also focus some production on high CBD strains, which contain only trace amounts of THC. CBD oil is legal in Canada, the USA and the EU, and is a prescription medicine in many countries.

Many countries have legalised cannabis for medical and/or recreational use, including Australia, Canada, many US states, South Africa, and many European countries.

- Legal for any use
- Legal as authorised by a physician



Cannabis Market

Botanapharm

Cannabis is an extremely high-value crop that commands premium prices.

The size of the Canadian market for medical cannabis is estimated at US\$1.3 billion. The size of the global market is over US\$180 billion.

Under the offtake agreement **Botanapharm** has signed, it will sell dried cannabis bud and sugar leaf at premium international prices.



US\$1.3 billion
Canadian market



US\$180 billion
Global market



Lesotho

Land and licenses secured.



Zimbabwe

Two JVAs signed. Land secured and licenses secured.



South Africa

Land (5.5 ha) secured. License application in progress.



Malta

Land secured. License application in progress.

Project	Country	License	Agreements	Crop	Area (ha)	Profit share	Comments
Kana Health	Lesotho	Granted	JVA signed.	Medical cannabis	5	80:20	First crop of 0.5 ha to be planted by early Feb 2020 under shade netting. Another 20 ha available.
Chikurubi with MOH	Zimbabwe	Granted	JVA signed with Ministry of Health. Shareholder agreement about to be issued. DLA Piper to finalise agreement.	Medical cannabis	20	60:40	Land allocated by Government in suburbs of Harare.
Carolina Wilderness	Zimbabwe	Feb 2020	JVA signed.	Industrial hemp	30	60:40	3,000 ha farm with tobacco crop and game reserve.
Weird Leaf Cannabis at Goromonzi	Zimbabwe	Granted	NDA signed. Heads of agreement to be signed Jan 2020.	Medical cannabis	20	60:40	Farm currently used to grow tobacco. Owned by investment banker, who can provide capital. Three farms available.
Tau Tsehla Medical Cannabis Development	Lesotho	Granted	MOU signed. JVA signed Jan 2020	Medical cannabis	10	70:30	Land in Special Economic Zone with major tax concessions. First Economic Zone in Lesotho. 10,000 ha available.
Medidope Pharmaceuticals	South Africa	Mar 2020	JVA signed.	Medical cannabis	5.5	70:30	Close to Johannesburg. Another 20 ha available



In 2017, Lesotho became the first African country to legalise the farming of cannabis for medicinal use.

Botanapharm has signed a JVA with Kana Health (Pty) Ltd, a company incorporated in Lesotho, to grow cannabis.

In August 2018, Kana Health was granted a 10-year licence by the Lesotho MOH to cultivate, manufacture, supply, hold, import, export and transit cannabis products.

By early February 2020, Kana Health is planning to plant 5,000 m² of crop under shade netting. This will be expanded to 75,000 m² over the following two years. A further 25 hectares is also available.

Master Plan Tau-Tsehla Medical Cannabis Development Property Zone

Botanapharm



Bophelo North

Future Expansion North

Future Expansion A

Future Expansion B

Future Expansion East


Future Expansion West

Bophelo South

Industrial Ship & Distribution

Master Plan Tau-Tsehla Medical Cannabis Development Property Zone

Botanapharm



Student Accommodation

University

Sport Complex

Staff Housing

Transport Center & Office

Laboratory & Office

Retail Strip

Training Center

Medical Centre

Botanapharm

To Mafeteng



To Maseru



To Tsa Kholo



To Tsa Kholo

To Maseru

To Mafeteng





Lesotho offers several advantages for growing cannabis:



Legislative support

in 2017, Lesotho was the first African country to legalise medical cannabis.



Ideal climate

over 300 days per year of sunshine, low humidity, pristine water, no need for high cost indoor growing facilities.



Educated workforce

pool of skilled, low-cost farm workers



Location

existing infrastructure for exporting to European and North American markets.



In addition to the above project sites, **Botanapharm** is in the processes of securing several other project sites in Africa and Malta.

South Africa

In January 2019, South Africa became the third African country to legalise cannabis for medicinal use. **Botanapharm** has secured 5.5 hectares of land in South Africa, suitable for growing cannabis. A JVA and license application are in progress.

Malta

In March 2018, Malta legalised cannabis for medical use. **Botanapharm** has also secured land in Malta. A license application is in progress.

Seeds and cuttings

A range of cannabis cultivars will be grown, including those suitable for medical applications and matched to local growing conditions. These will include fast growing *C. ruderalis* varieties, which can be harvested approximately 70 days after germination. **Botanapharm** will also establish nurseries to grow cannabis plants from seed. These will be used to produce seed or propagated vegetatively to progressively plant out at least 10 hectares. Harvesting will begin in Q1 2021.

Cultivation

Greenhouses, polytunnels and hoop shade netting will be used with drip irrigation to feed and water plants. Beginning with the Kana Health land in Lesotho, **Botanapharm** plans to plant 5,000 m² of irrigated crop under shade netting by mid-December 2019, to take advantage of the coming summer. This has been costed at about A\$260,000.

Drying and processing

Harvested material will be dried in drying rooms to allow for uniform drying and prevent any mould growth. Oil and resin can be extracted using processes such as supercritical fluid extraction.



Botanapharm has signed an offtake agreement with a German-based wholesaler, distributor and importer of medical products, including medical cannabis, for the European market.

Under this agreement, **Botanapharm** will sell dried cannabis bud and sugar leaf.

Botanapharm may also supply medicinal cannabis products to meet demand in Lesotho and South Africa,



George Sim

Global Chief Financial Officer & Interim Chief Executive Officer, and Founding Director of Botanapharm

George is a Chartered Accountant who, after a number of years at partner level, now specializes in corporate finance as the Managing Director of Winning Corporate Services. He has previously worked as a partner, CFO, company secretary and financial controller for various companies, and has been a member of the Institute of Chartered Accountants of Scotland for 30 years. Over the past 10 years, George has established investor groups in Hong Kong, Singapore, Taipei, Tokyo, New York, London and every Australian state. He has listed companies on ASX, NASDAQ and Frankfurt second board.



Adrian Love

Head, Global Network & Partnerships & Business Development, and Founding Director of Botanapharm

Adrian is a licensed financial advisor, working in the financial services industry for the past 30 years. Originally from the UK, he has been based in Singapore for the past 18 years. He has held various directorships, helping businesses expand and grow. He combines experience with a creative mindset and believes in taking a human centred approach, guiding businesses to be successful while being environmentally beneficial.



Robert Mkombachoto

Managing Director of Botanapharm South Africa and Founding Director of Botanapharm South Africa

Robert is an experienced serial entrepreneur who has been an investor in and director of numerous start-up companies, spanning a range of businesses including electrical equipment, bricks and pavers, waste recycling and fibre optic civil works. In 2002, he helped established Global Foreign Exchange, the first Blackowned Bureau de Change in post-apartheid South Africa. His most recent venture is the coal trading company Romax Investments. Prior to 1995, he worked in the Zimbabwe civil service on trade and developmental issues. Robert is Botanapharm's business development manager in Africa.



Matthew Carabott

Chief Technical Officer and Founding Director of Botanapharm

Matthew is Head Agronomist (Asia Pacific) for Eurochem, one of the world's largest agrichemical companies. Based in Singapore, he is responsible for general technical support, research and development, and managing the regulatory requirements for the region. Prior to joining Eurochem, Matthew worked as an internal advisor in fruit and vegetable production for Woolworths, Australia's largest supermarket chain. He has also managed an organic hydroponic farm, designating nutrient solutions and precision growing systems. Matthew holds a Bachelor of Biological Science from Latrobe University with Honours in Biochemistry.



Glen Tomlinson

Head Grower and Partner – Carolina Estates & Chikurubi

Glen is Managing Director of Carolina Estates P/L. Glen is a renowned 3rd Generation Tobacco Farmer and owner /operator of family owned Carolina Wilderness. Carolina Wilderness is partly used as a sanctuary for endangered species of wild animals and doubles as a wild game viewing park. The farm lies adjacent to Lake Chivero, which can provide a source of irrigation water. The farm is surrounded by excellent sealed road infrastructure and is located about 27 km from Harare International Airport, currently the only legal route for exporting cannabis from Zimbabwe.




Neall Ellis

Security Advisor & Partner – Kana Health Lesotho

“Neall” is a decorated South African military aviator. After retiring from the SAAF he contracted for various private military corporations, including Executive Outcomes and Sandline International. During the civil war in Sierra Leone, he and his crew held off Revolutionary United Front (RUF) forces almost single-handedly. He also provided fire support for British troops during Operation Barras. Neall is responsible for the security measures on all Botanapharm Grow Sites. This includes 24-hour crop surveillance, site risk assessment and risk mitigation, secured logistics and corporate intelligence measures.

	2020			2021			
	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Income							
Seed capital	500,000						
Share capital	35,000						
Funds from public company listing		1,500,000					
Sale of raw cannabis							
Crop 1 (0.25 ha under shade netting)				5,000,000	5,000,000	5,000,000	
Crop 2 (0.75 ha of Ruderalis)					15,000,000		15,000,000
Crop 3 (1ha)							20,000,000
Crop 4 (1 ha)							20,000,000
Crop 5 (2 ha)							
<u>Total income</u>	535,000	1,500,000	-	5,000,000	20,000,000	5,000,000	55,000,000
<u>Total expenses</u>	25,000		408,679	1,713,129	4,185,879	1,890,879	11,135,879
<u>Cash flow</u>	510,000	1,500,000	(408,679)	3,286,871	15,814,121	3,109,121	43,864,121
<u>Opening balance</u>		510,000	2,010,000	1,601,321	4,888,192	20,702,313	23,811,434
<u>Closing balance</u>	510,000	2,010,000	1,601,321	4,888,192	20,702,313	23,811,434	67,675,555

BOTANAPHARM PTY LIMITED





THANK YOU

This presentation contains confidential information and is intended for information purposes only. This presentation is proprietary to Botanapharm and intended solely for the use of the individual or entity to whom it is addressed and is not to be disseminated, distributed or copied.